These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 37238938)
1. RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer. Koumarianou A; Ntavatzikos A; Symeonidis D; Vallilas C; Giannakakou M; Papaxoinis G; Xynogalos S; Boukovinas I; Demiri S; Kampoli K; Oikonomopoulos G; Samantas E; Res E; Androulakis N; Vourli G; Souglakos I; Karamouzis M Biomedicines; 2023 Apr; 11(5):. PubMed ID: 37238938 [TBL] [Abstract][Full Text] [Related]
2. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer. Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008 [No Abstract] [Full Text] [Related]
3. Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer. Kasper S; Kisro J; Fuchs M; Müller C; Schulz-Abelius A; Karthaus M; Rafiyan MR; Stein A BMC Cancer; 2018 Nov; 18(1):1124. PubMed ID: 30445951 [TBL] [Abstract][Full Text] [Related]
4. Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. Mayer RJ; Hochster HS; Cohen SJ; Winkler R; Makris L; Grothey A Cancer Chemother Pharmacol; 2018 Dec; 82(6):961-969. PubMed ID: 30350179 [TBL] [Abstract][Full Text] [Related]
5. Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center. Patel AK; Abhyankar R; Brais LK; Duh MS; Barghout VE; Huynh L; Yenikomshian MA; Ng K; Fuchs CS Oncologist; 2021 Dec; 26(12):e2161-e2169. PubMed ID: 34406678 [TBL] [Abstract][Full Text] [Related]
6. Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer. Van Cutsem E; Hochster H; Shitara K; Mayer R; Ohtsu A; Falcone A; Yoshino T; Doi T; Ilson DH; Arkenau HT; George B; Benhadji KA; Makris L; Tabernero J ESMO Open; 2022 Dec; 7(6):100633. PubMed ID: 36455504 [TBL] [Abstract][Full Text] [Related]
7. Impact of KRAS Tabernero J; Taieb J; Fakih M; Prager GW; Van Cutsem E; Ciardiello F; Mayer RJ; Amellal N; Skanji D; Calleja E; Yoshino T ESMO Open; 2024 Mar; 9(3):102945. PubMed ID: 38471240 [TBL] [Abstract][Full Text] [Related]
8. Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study. Nose Y; Kagawa Y; Hata T; Mori R; Kawai K; Naito A; Sakamoto T; Murakami K; Katsura Y; Ohmura Y; Masuzawa T; Takeno A; Takeda Y; Kato T; Murata K Cancer Chemother Pharmacol; 2020 Sep; 86(3):427-433. PubMed ID: 32816155 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany. Kröning H; Göhler T; Decker T; Grundeis M; Kojouharoff G; Lipke J; Semsek D; Moorahrend E; Sauer A; Bruch HR; Liersch R; Nusch A; Vehling-Kaiser U; Welslau M; Grunewald R; Harich HD; Stephany M; Uhlig J; de Buhr R; Frank M; Hogrefe C; Marschner N; Potthoff K; Hartmann F; Reisländer T; Schwaner I Int J Cancer; 2023 Sep; 153(6):1227-1240. PubMed ID: 37260368 [TBL] [Abstract][Full Text] [Related]
10. Trifluridine/tipiracil as a therapeutic option in real life setting of metastatic colorectal cancer: An efficacy and safety analysis. Sur D; Lungulescu C; Spînu Ș; Gorzo A; Dumitrescu EA; Gheonea DI; Lungulescu CV Front Pharmacol; 2022; 13():1041927. PubMed ID: 36313317 [No Abstract] [Full Text] [Related]
11. Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan. Kagawa Y; Shinozaki E; Okude R; Tone T; Kunitomi Y; Nakashima M ESMO Open; 2023 Aug; 8(4):101614. PubMed ID: 37562196 [TBL] [Abstract][Full Text] [Related]
12. Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study". Coutzac C; Trouilloud I; Artru P; Henriques J; Masson T; Doat S; Bouché O; Coriat R; Saint A; Moulin V; Vernerey D; Gallois C; De La Fouchardière C; Tougeron D; Taieb J Clin Colorectal Cancer; 2022 Jun; 21(2):132-140. PubMed ID: 35337742 [TBL] [Abstract][Full Text] [Related]
14. Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis. Yoshino T; Taieb J; Kuboki Y; Pfeiffer P; Kumar A; Hochster HS Ther Adv Med Oncol; 2023; 15():17588359221146137. PubMed ID: 36743525 [TBL] [Abstract][Full Text] [Related]
15. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer. Moehler M; Michel M; Stein A; Trojan J; Marquardt J; Tintelnot J; Waidmann O; Weinmann A; Woerns MA; Schroeder H; Maenz M; Foerster F Future Oncol; 2021 Sep; 17(25):3309-3319. PubMed ID: 33993741 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study. Bazarbashi S; Alkhatib R; Aseafan M; Tuleimat Y; Abdel-Aziz N; Mahrous M; Elsamany S; Elhassan T; Alghamdi M JCO Glob Oncol; 2024 Mar; 10():e2300461. PubMed ID: 38484194 [TBL] [Abstract][Full Text] [Related]
17. Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G). Takahashi N; Hara H; Nagashima K; Hirata K; Masuishi T; Matsumoto T; Kawakami H; Yamazaki K; Hironaka S; Boku N; Muro K BMC Cancer; 2023 Aug; 23(1):726. PubMed ID: 37543568 [TBL] [Abstract][Full Text] [Related]
18. Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab. Kamiimabeppu D; Osumi H; Shinozaki E; Ooki A; Wakatsuki T; Yoshino K; Sato T; Nakayama I; Ogura M; Takahari D; Chin K; Yamaguchi K Oncol Lett; 2021 Nov; 22(5):783. PubMed ID: 34594424 [TBL] [Abstract][Full Text] [Related]
19. Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib. Patel AK; Barghout V; Yenikomshian MA; Germain G; Jacques P; Laliberté F; Duh MS Oncologist; 2020 Jan; 25(1):e75-e84. PubMed ID: 31591140 [TBL] [Abstract][Full Text] [Related]
20. Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer. Arrichiello G; Perrone A; Napolitano S; Martini G; De Falco V; Incoronato P; Laterza MM; Facchini G; Famiglietti V; Nacca V; Paragliola F; Napolitano R; Suarato G; Nicastro A; Martinelli E; Ciardiello D; Ciardiello F; Troiani T Target Oncol; 2022 Nov; 17(6):635-642. PubMed ID: 36239883 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]